Quoc Truong1, Nilay Shah1, Mark Knestrick2, Brendan Curley1, Yanqing Hu3, Michael Craig4, Mehdi Hamadani5. 1. Myeloma and Lymphoma Service, West Virginia University, Morgantown, WV. 2. Department of Internal Medicine, West Virginia University, Morgantown, WV. 3. Department of Statistics, West Virginia University, Morgantown, WV. 4. Myeloma and Lymphoma Service, West Virginia University, Morgantown, WV; Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV. 5. Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV. Electronic address: mehdi.hamadani@gmail.com.
Abstract
INTRODUCTION: Surveillance imaging with computed tomography (CT) or positron emission tomography with CT (PET/CT) is commonly used in practice in patients with non-Hodgkin lymphoma (NHL) who are in remission after front-line therapies. We aimed to determine the utility of routine imaging for detecting first relapse in patients with NHL in complete remission (CR) after first-line therapies. PATIENTS AND METHODS: We retrospectively analyzed patients with NHL who achieved CR after first-line therapies and then subsequently had disease relapse. We evaluated whether the relapse was detected solely by surveillance CT or PET/CT or by patient-reported symptoms or physical examination findings, or both. Subgroup analysis was performed on baseline histologic type (indolent vs. aggressive NHL). Data were also collected to determine the cost of surveillance PET/CT and the number of additional diagnostic imaging procedures, invasive procedures, and iatrogenic complications directly resulting from an abnormality detected on a surveillance scan. RESULTS: One hundred sixty-three patients with first relapse of NHL between January 1, 2000 and December 31, 2010 were included. The majority of the relapses were detected by patient-reported symptoms or physical examination, or both, as opposed to surveillance imaging (77.9% [n = 127] vs. 22.1% [n = 36]; P < .0001). There was no overall survival difference between the 2 groups (P = .66). Patient-reported symptoms led to the detection of the majority of relapses in aggressive (85.7% [n = 72] vs. 14.3% [n = 12]; P < .0001) as well as indolent NHL (69.6% [n = 55] vs. 30.4% [n = 24]; P = .0007). Surveillance PET/CT contributed to more than 75% of follow-up health care costs in the first 2 years of monitoring for relapse. The surveillance imaging group had 1 reported case of iatrogenic pneumothorax. CONCLUSION: Our retrospective analysis suggests that there is a limited role for surveillance imaging by CT or PET/CT in detecting first relapse in NHL. There was no difference in survival outcomes between the 2 groups in our study.
INTRODUCTION: Surveillance imaging with computed tomography (CT) or positron emission tomography with CT (PET/CT) is commonly used in practice in patients with non-Hodgkin lymphoma (NHL) who are in remission after front-line therapies. We aimed to determine the utility of routine imaging for detecting first relapse in patients with NHL in complete remission (CR) after first-line therapies. PATIENTS AND METHODS: We retrospectively analyzed patients with NHL who achieved CR after first-line therapies and then subsequently had disease relapse. We evaluated whether the relapse was detected solely by surveillance CT or PET/CT or by patient-reported symptoms or physical examination findings, or both. Subgroup analysis was performed on baseline histologic type (indolent vs. aggressive NHL). Data were also collected to determine the cost of surveillance PET/CT and the number of additional diagnostic imaging procedures, invasive procedures, and iatrogenic complications directly resulting from an abnormality detected on a surveillance scan. RESULTS: One hundred sixty-three patients with first relapse of NHL between January 1, 2000 and December 31, 2010 were included. The majority of the relapses were detected by patient-reported symptoms or physical examination, or both, as opposed to surveillance imaging (77.9% [n = 127] vs. 22.1% [n = 36]; P < .0001). There was no overall survival difference between the 2 groups (P = .66). Patient-reported symptoms led to the detection of the majority of relapses in aggressive (85.7% [n = 72] vs. 14.3% [n = 12]; P < .0001) as well as indolent NHL (69.6% [n = 55] vs. 30.4% [n = 24]; P = .0007). Surveillance PET/CT contributed to more than 75% of follow-up health care costs in the first 2 years of monitoring for relapse. The surveillance imaging group had 1 reported case of iatrogenic pneumothorax. CONCLUSION: Our retrospective analysis suggests that there is a limited role for surveillance imaging by CT or PET/CT in detecting first relapse in NHL. There was no difference in survival outcomes between the 2 groups in our study.
Authors: J Sussman; N P Varela; M Cheung; L Hicks; D Kraftcheck; J Mandel; G Fraser; L Jimenez-Juan; A Boudreau; S Sajkowski; R McQuillan Journal: Curr Oncol Date: 2016-10-25 Impact factor: 3.677
Authors: Ka-Won Kang; Se Ryeon Lee; Dae Sik Kim; Eun Sang Yu; Hwa Jung Sung; Seok Jin Kim; Chul Won Choi; Yong Park; Byung Soo Kim Journal: PLoS One Date: 2018-02-14 Impact factor: 3.240
Authors: Max L Goldman; Jimmy J Mao; Christopher S Strouse; Wanqi Chen; Manali Rupji; Zhengjia Chen; Matthew J Maurer; Oscar Calzada; Michael Churnetski; Christopher R Flowers; James R Cerhan; Brian K Link; Carrie A Thompson; Jonathon B Cohen Journal: Cancer Date: 2021-06-22 Impact factor: 6.921